




 Lung transplantation is the only established treat-ment to prolong survival among individuals with 
end-stage lung disease, but the median survival time 
following transplant is only 5.0 years. 1 Accordingly, 
there is increasing interest in identifying factors that 
might infl uence posttransplant survival. A number of 
clinical and demographic predictors have been iden-
tifi ed, including older age, reduced functional capacity, 
and lower FEV 1 prior to surgery. 2,3 
 Greater neuropsychiatric symptoms, including depres-
sion and anxiety, have been observed among lung trans-
plant candidates, with as many as 25% of lung transplant 
patients meeting diagnostic criteria for a mood or anx-
iety disorder. 4 Several studies have also examined psy-
chosocial factors as predictors of mortality among lung 
transplant patients. 5,6 Evon and colleagues 5 found that 
depression was associated with poorer wait-list sur-
vival among lung transplant candidates, but that this 
 Background:  Neurobehavioral functioning is widely recognized as being an important consider-
ation in lung transplant candidates, but little is known about whether these factors are related to 
clinical outcomes. The present study examined the relationship of neurobehavioral functioning, 
including measures of executive function and memory, depression, and anxiety, to long-term sur-
vival among lung transplant recipients. 
 Methods:  The sample was drawn from 201 patients who underwent transplantation at Duke Uni-
versity and Washington University who participated in a dual-site clinical trial investigating med-
ical and psychosocial outcomes in transplant candidates with end-stage lung disease. All patients 
completed the Beck Depression Inventory-II (BDI-II) and Spielberger State-Trait Anxiety Inven-
tory at baseline and again after 12 weeks, while a subset of 86 patients from Duke University 
also completed neurocognitive testing. Patients were followed for survival up to 12 years after 
completing baseline assessments. 
 Results:  One hundred eleven patients died over a mean follow-up of 10.8 years (SD  5 0.8). Baseline 
depression, anxiety, and neurocognitive function were examined as predictors of posttransplant 
survival, controlling for age, 6-min walk distance, FEV, and native disease; education and cardio-
vascular risk factors were also included in the model for neurocognition. Lower executive func-
tion (hazard ratio [HR]  5 1.09,  P  5 .012) and memory performance (HR  5 1.11,  P  5 .030) were 
independently associated with greater mortality following lung transplant. Although pretransplant 
depression and anxiety were not predictive of mortality, patients who scored  . 13 on the BDI-II 
at baseline and after 3 months pretransplant had greater mortality (HR  5 1.85 [95% CI, 1.04, 3.28], 
 P  5 .036). 
 Conclusions:  Neurobehavioral functioning, including persistently elevated depressive symp-
toms and lower neurocognitive performance, was associated with reduced survival after lung 
transplantation. 
 Trial registry:  ClinicalTrials.gov; No.: NCT00113139; URL: www.clinicaltrials.gov  
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 Materials and Methods 
 The study used data collected for the INSPIRE trial, a ran-
domized, controlled trial of a telephone-based coping skills inter-
vention for lung transplant patients. 16 Participants were enrolled 
either at Duke University Medical Center (DUMC) or Washington 
University School of Medicine (WUSM) in St. Louis from their 
respective transplant waiting lists. As previously reported, 16 individ-
uals were enrolled in the INSPIRE trial between September 2000 
and August 2004. Primary results showed that the coping skills 
intervention signifi cantly improved quality of life relative to health 
education controls, but did not result in improved survival. The 
study was approved by the DUMC (institutional review board 
[IRB] #9150) and WUSM (IRB #00-0861) IRBs. 
 Data on FEV 1 17 were obtained from the participant’s medical 
records. Exercise tolerance based on a 6-min walk test 18 was 
assessed by an experienced physical therapist at a dedicated pul-
monary rehabilitation facility at either DUMC or WUSM. The 
Framingham Stroke Risk Profi le 19 (FSRP) was obtained to account 
for the potentially confounding effects of medical comorbidities. 
The FSRP includes multiple stroke risk factors, including sys-
tolic BP, diabetes, left ventricular hypertrophy, and atrial fi brilla-
tion and was determined from the most recent pulmonary clinic 
assessment prior to patient’s neurocognitive testing session. 
 Neurobehavioral Assessments 
 Participants completed a battery of questionnaires and, for 
DUMC participants, a neurocognitive test battery at the time of 
enrollment in the INSPIRE trial. As reported in a separate publi-
cation examining the impact of transplantation on neurocognition, 
our test battery was selected for the availability of normative data, 
alternate test forms, and demonstrated predictive ability in other 
studies. 20 
 The Beck Depression Inventory (BDI)-II, 21 a 21-item self-
report questionnaire, was used to assess symptoms of depression. 
Items consist of statements that are scored on a range of 0 to 3, 
depending on symptom severity, with higher scores indicating 
greater depressive symptoms. The BDI-II has previously been 
shown to have good internal consistency, with a mean coeffi cient 
 a value of 0.86 among psychiatric patients. In addition to baseline 
BDI scores, BDI scores were obtained after the 12-week INSPIRE 
intervention. 16 Elevated depressive symptoms were defi ned as a 
BDI-II score   14. Persistent depression was defi ned as depres-
sive symptoms  . 13 on both occasions; participants who obtained 
BDI scores  . 13 at baseline but  , 14 after 12 weeks were consid-
ered remitted. 
 The 20-item state subscale of the Spielberger State-Trait Anxi-
ety Inventory (STAI-S) 22 was used to assess the current severity of 
anxiety. Higher scores on the STAI-S indicate a greater state of 
anxiety and the STAI-S has a test-retest reliability of 0.62. 
 Pretransplant neurocognitive assessments were conducted only 
at Duke University. The assessments included measures of mem-
ory, executive function, and processing speed. Neurocognitive 
tests included the Trail Making Test (TMT) A and B, 23 the Stroop 
Test, 24 the Ruff 2&7 Test, 25 the Wechsler Adult Intelligence Scale 
Digit Symbol Substitution Test (DSST), 26 the Wechsler Adult 
Intelligence Scale Digit Span Test, 26 the Wechsler Memory Scale 
Verbal Paired Associates and Logical Memory subtests, 27 the 
Controlled Oral Word Association Test, 28 and the Animal Naming 
Test. 28 
 Posttransplant Survival 
 DUMC and WUSM medical records were reviewed to confi rm 
participant’s date of transplantation, as well as survival status, and 
date of death. If no date of death was found in a patient’s medical 
association was attenuated after controlling for demo-
graphic characteristics and severity of pulmonary dis-
ease. Several studies also have examined elevated anxiety 
and posttransplant outcomes. For example, the pres-
ence of posttraumatic stress disorder has been associ-
ated with signifi cantly greater posttransplant mortality 
in heart patients 7 and anxiety has been associated with 
greater risk of physical impairment following lung 
transplantation. 8 However, to our knowledge, no study 
has examined the relationship between pretransplant 
depression, anxiety, and posttransplant clinical out-
comes in lung patients. 
 In addition to the relatively small literature on pre-
transplant psychologic functioning, no studies have 
examined persistent depression or neurocognitive dys-
function as predictors of mortality in this patient group, 
despite the prevalence of neurobehavioral dysfunc-
tion. 9 Persistent depression, typically defi ned as depres-
sive symptoms that remain elevated over the course 
of several months, 10 has been associated with increased 
mortality following coronary artery bypass grafting . 11 
Lower cognitive function, which is typically measured 
by performance on tests of memory, attention, and 
concentration, 12 has been associated with increased 
mortality in epidemiologic studies of primary care 
patients 13,14 and among cardiac patients, 15 but has not 
been examined as a predictor of outcomes following 
lung transplantation. The objective of the present study 
was to examine several indexes of pretransplant neu-
robehavioral functioning, including depression, anxiety, 
and neurocognitive performance, as predictors of mor-
tality following lung transplant among recipients who 
had participated in the Investigational Study of Psy-
chological Intervention in Recipients of Lung Trans-
plant (INSPIRE) clinical trial. 
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 Results 
 Background and clinical characteristics are presented 
in  Table 1 . Two hundred one INSPIRE participants 
underwent transplantation between September 2000 
and September 2008 (Fig 1). Follow-up time was an 
average of 9.2 years (SD  5 1.5; range, 4-12 years) 
following transplantation, which corresponded to an 
average of 10.8 years (SD  5 0.8) following study enroll-
ment. Across all participants the median survival time was 
5.1 years (interquartile range  5 5.8 years). Partici pants 
received transplants approximately 1.5 years follow-
ing the completion of their posttreatment assessments 
(1.44 [SD  5 1.22] years). Of the original 389 patients 
enrolled in the INSPIRE trial, 201 patients (52%) 
underwent transplantation between September 2000 
and September 2008, and by January 2012, 111 of 
those who received transplants had died (55%). The 
most common native disease diagnosis was COPD 
(42%), followed by PF (22%), and CF (19%). Other 
indications included  a 1  antitrypsin defi ciency, pri-
mary pulmonary hypertension, lymphangioleiomyo-
matosis, bronchiectasis, sarcoidosis, and Eisenmenger 
syndrome. The primary causes of death were graft 
failure (38, 34.5%), pulmonary causes (19, 17.3%), 
and rejection (17, 15.5%). Other causes of death 
included cardio/cerebrovascular (six, 5.4%), hemor-
rhage (three, 2.7%), infection (seven, 6.4%), malig-
nancy (seven, 6.4%), multiorgan failure (six, 5.4%), and 
unknown causes (seven, 6.4%). 
 Depression and Anxiety 
 The relationship of pretransplant depressive symp-
toms and anxiety to mortality was assessed. Sixty-nine 
participants (34%) were depressed (ie, BDI-II   14) 
at baseline. Baseline depression scores were not asso-
ciated with survival after accounting for demographic 
and medical factors (hazard ratio [HR]  5 1.01 [95% CI, 
0.98, 1.03],  P  5 .375). Baseline scores on the STAI-S 
also were not associated with increased mortality 
(HR  5 1.00 [95% CI, 0.98, 1.02],  P  5 .796). 
 Persistent and remitted depression was also evalu-
ated. Among the 132 individuals with both pretreat-
ment and posttreatment BDI-II scores, 74 individuals 
died over the 10-year follow-up period. Of these, 
44 individuals had elevated depressive symptoms at 
baseline. In 23 of these individuals, their depressive 
symptoms remained elevated after 3 months (ie, had 
persistent depression), whereas 21 individuals showed 
remission of depressive symptoms (BDI-II scores  , 14 
after 3 months). Of the 23 who had persistent depres-
sion (ie, BDI   14 at baseline and after 12 weeks), 
17 died (74%). Those patients with persistently ele-
vated depressive symptoms were more likely to die 
over the follow-up period after transplantation com-
pared with participants who were not depressed at 
record, a Social Security Death Index search was conducted to 
confi rm status as alive or dead on every patient as of January 1, 
2012. 
 Statistical Analyses 
 Psychosocial predictors of posttransplant survival were carried 
out in separate proportional hazards models for each psychosocial 
predictor using Proc Phreg in SAS 9.2 (SAS Institute Inc). We 
conducted separate analyses using baseline BDI-II, persistent 
depression (BDI-II   14 at both baseline and following coping 
skills treatment), and STAI-S as our predictors of interest. To con-
trol for potential medical factors that would also infl uence mor-
tality, we controlled for background and medical factors that have 
previously been associated with poorer survival time following 
transplantation. Specifi cally, we controlled for age, time on wait list, 
FEV 1 , 6-min walk distance, and native disease as our covariates. 
Medical covariates were scaled for consistency with previous anal-
yses of the INSPIRE cohort. 3 Because the majority of participants 
(n  5 196) received bilateral lung transplantation, we did not con-
trol for type of lung transplant. Age was scaled by 10-year age 
increments, FEV 1 was quantifi ed as percent of predicted FEV 1 and 
was scaled in 10-percentage point increments, 6-min walk distance 
was scaled in increments of 500 feet, FSRP was left unscaled, and 
native disease was classifi ed into indicator variables of the presence 
or absence of cystic fi brosis (CF), COPD, pulmonary fi brosis (PF), 
or other. 
 For our analyses of neurocognitive function, we also controlled 
for years of education because of the infl uence of premorbid edu-
cation on both cognition and overall health, as well as the FSRP 
because of the potentially confounding effects of cardiovascular 
health. In these analyses, our unit-weighted composite measures 
of memory and executive function served as our predictors of 
interest in separate models. These models further controlled for 
age, time on wait list, FEV 1 , 6-min walk distance, FSRP, and native 
disease category. 
 Neurocognitive function subtests were combined to minimize 
the number of statistical tests in the present analysis. Principal 
component analysis was used to combine the information from the 
13 individual neurocognitive tests into two neurocognitive domains: 
executive function and memory. A scree test was used to deter-
mine the total number of factors retained for analysis. A minimum 
loading of 0.50 was required, and varimax rotation was used. Proc 
Factor was used to conduct the factor analyses in SAS 9.2. Based 
on these results, we created unit-weighted composite scores by stan-
dardizing the individual neuropsychologic test scores and then sum-
ming all subtests relevant to a given domain. Our executive function 
composite included the Digit Symbol Substitution Test, TMT-A, 
TMT-B, Stroop Word, Color, and Color-Word, and the Ruff 2&7 
test. Our memory composite variable included the Wechsler Adult 
Intelligence Scale Digit Span Test forward and backward, Verbal 
Paired Associates, and Logical Memory tests. These composites 
were then used as the predictors of interest in separate propor-
tional hazards regression analyses due to their colinearity. 
 The independent association between each predictor and cova-
riate was fi rst examined using separate Kaplan-Meier analyses 
using Proc Lifetest in SAS version 9.2 (SAS Institute Inc). Because 
participants included in the present analysis were not equally 
distributed in their assignment to treatment, we fi rst examined 
whether there was any difference in survival between the two 
treatment groups. We found no evidence of a treatment effect 
when the entire sample was examined and also found no differen-
tial treatment group effect in our analyses of persistent depres-
sion. For our analyses of posttransplant depression and anxiety, 
our analyses were limited to a subset of patients who were still 
living and available for assessment 18 months following their 
transplantation. 
journal.publications.chestnet.org CHEST / 145 / 3 / MARCH 2014  607 
also associated with decreased survival (HR  5 1.13 
[95% CI, 1.01, 1.28],  P  5 .039). Because only 86 par-
ticipants underwent neurocognitive assessments, we 
compared participants with and without neurocogni-
tive testing at DUMC to determine whether this sub-
set of participants was similar to the larger sample. 
Patients did not differ from untested patients regard-
ing age ( P  5 .266), education ( P  5 .184), depression 
( P  5 .322), FEV 1 ( P  5 .189), or 6-min walk distance 
( P  5 .194). However, among participants from DUMC, 
those participants who underwent testing exhibited 
lower STAI-S scores ( P  5 .038) compared with par-
ticipants at DUMC who did not. 
 Discussion 
 This study examined the relationship between pre-
transplant neurobehavioral functioning and posttrans-
plant mortality in a subgroup of patients who had 
participated in the INSPIRE trial. Over 10.8 years of 
follow-up time from enrollment, 111 patients (55%) 
died with a median survival time of 5.1 years following 
transplantation. Interestingly, none of the pretransplant 
medical covariates examined in our study was pre-
dictive of mortality. In addition, we did not observe any 
relationship between baseline pretransplant depres-
sion or anxiety and posttransplant mortality. How-
ever, in ancillary analyses, we found that depression 
that persisted from baseline to 3 months, along with 
several neurocognitive measures obtained at baseline, 
prior to transplant, were predictive of survival. In addi-
tion, the presence of elevated depressive symptoms 
either time point or who had depressive symptoms at 
one time point only (HR  5 1.85 [95% CI, 1.04, 3.28], 
 P  5 .036) ( Fig 2 ). No other predictors were signifi -
cantly associated with mortality in this model. In con-
trast, 13 of 21 individuals (62%) who had elevated 
depressive symptoms at baseline and subsequently 
remitted after 3 months (BDI-II scores  , 14) had died. 
Depression remission was not a signifi cant predictor 
of survival (HR  5 0.96 [95% CI, 0.32, 2.84],  P  5 .949). 
 For posttransplant depression and anxiety, 96 indi-
viduals had 18-month psychosocial follow-up data avail-
able for analysis. Among individuals with 18-month 
follow-up data, 45 subsequently died. After control-
ling for age, native disease, and FEV 1 measured at 
18-month follow-up, we found that greater depressive 
symptoms at 18 months were associated with increased 
risk of mortality (HR  5 1.07 [95% CI, 1.01, 1.13], 
 P  5 .015). No other medical predictors were asso-
ciated with mortality in this model. Posttransplant 
anxiety was not associated with increased mortality 
(HR  5 1.02 [95% CI, 0.97, 1.06],  P  5 .512). 
 Pretransplant Neurocognitive Function 
and Mortality 
 Among the 86 patients from DUMC who completed 
the pretransplant neurocognitive testing, 48 died over 
the 10-year follow-up period. Poorer executive  func-
tion at baseline was associated with worse survival 
(HR  5 1.09 [95% CI, 1.02, 1.17],  P  5 .012) ( Table 2 ). 
Worse memory performance also predicted worse 
survival (HR  5 1.11 [95% CI, 1.01, 1.23],  P  5 .030) 
( Table 3 ). Within this model, higher FSRP levels were 
 Table 1— Pretransplant Demographic and Medical Characteristics of the Entire Sample 
 Variable  COPD (n  5 85)  CF (n  5 39)  PF (n  5 44)  Other (n  5 33)  Cohort (n  5 201) 
Age, y 57.5 (5.7) 30.2 (8.0) 54.7 (8.7) 42.4 (11.3) 49.1 (13.2)
6-min walk, distance in ft 1000 (333) 1352 (302) 1259 (403) 1043 (441) 1131 (390)
FVC, a L 2.1 (0.6) 1.9 (0.6) 2.1 (0.8) 2.6 (0.9) 2.11 (0.7)
FEV 1 , a % predicted 19.8 (5.6) 26.1 (5.8) 50.7 (15.8) 41.8 (23.7) 31.4 (18.0)
Pa co 2 , b mm Hg 46.1 (8.6) 41.6 (5.3) 40.3 (3.7) 37.9 (7.3) 42.7 (7.6)
Pa o 2 , c mm Hg 62.5 (9.6) 65.0 (8.4) 65.2 (12.1) 65.2 (16.9) 64.0 (11.4)
Wait time, y 1.8 (1.5) 1.5 (1.5) 1.7 (1.5) 3.0 (3.2) 1.9 (1.9)
Education,  . HS (%) 45 (53) 35 (88) 31 (70) 20 (66) 131 (65)
Female (%) 55 (65) 28 (70) 23 (53) 17 (53) 123 (61)
BDI-II 12.2 (7.9) 9.9 (6.1) 10.4 (6.3) 13.2 (9.3) 11.5 (7.5)
STAI-S 38.2 (11.3) 33.8 (8.0) 34.4 (8.7) 38.0 (12.9) 36.5 (10.6)
Memory d  2 0.17 (3.26) 1.54 (3.67)  2 0.07 (3.58)  2 1.53 (2.82)  2 0.02 (3.46)
Executive function d  2 0.92 (5.95) 1.83 (4.97) 0.19 (4.5) 0.33 (4.6) 0.25 (5.14)
Survival, y 5.1 (3.0) 5.4 (3.4) 4.4 (2.8) 4.8 (3.6) 5.0 (3.1)
Data in parentheses are given as SD unless otherwise indicated. BDI  5 Beck Depression Inventory; CF  5 cystic fi brosis; HS  5 high school; 
PF  5 pulmonary fi brosis; STAI-S  5 Spielberger Anxiety Inventory-State version.
 a FVC and FEV 1 data were available for 200 patients.
 b Pa co 2 data for 196 patients.
 c Pa o 2 data were available for 197 patients.
 d Data for memory and executive function variables were available for 86 patients from Duke University Medical Center only. Executive function 
and memory data are presented as z-scores.
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mation regarding mortality risk following transplant 
beyond risk stratifi cation based on medical character-
istics alone. 
 Previous studies have suggested that poorer psycho-
social function may be predictive of increased mortality 
following transplant. Elevated depressive symptoms, 5 
obtained in a subset of patients 18 months follow-
ing transplantation was predictive of subsequent mor-
tality. These fi ndings suggest that worse performance 
on pretransplant measures assessing processing speed, 
executive function, and memory and posttransplant 
depression may provide important prognostic infor-
 Figure 1. Flowchart of participants. Of the 201 INSPIRE participants who received transplants, 132 
had both preintervention and postintervention depression assessments. Participants without posttreat-
ment data were on the waitlist for a shorter amount of time compared with participants in the control 
condition (1.27 [SD  5 2.07] y vs 2.25 [SD  5 1.78] y,  P  , .001). In addition, because Washington University 
School of Medicine did not perform neurocognitive assessments, only 86 participants from Duke Uni-
versity Medical Center completed neurocognitive assessments. These patients tended to be less anxious 
compared with those persons who did not complete the testing. INSPIRE  5 Investigational Study of 
Psychological Intervention in Recipients of Lung Transplant. 
 Figure 2. Kaplan-Meier survival curves of persistent depression and posttransplant survival. Partici-
pants with persistent depressive symptoms were more likely to die during the study follow-up compared 
with participants without persistent depressive symptoms (hazard ratio  5 1.85,  P  5 .036). 
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at greater risk for negative health outcomes following 
transplant and should be monitored closely. 
 The present study also found evidence that poorer 
neurocognitive function on tests of executive function 
and memory was predictive of mortality. Although no 
studies have examined pretransplant neurocognitive 
function as a predictor of mortality, previous studies 
have found that neurocognitive dysfunction may 
adversely impact medication compliance and that it is 
independently predictive of mortality in the general 
population. Neurocognitive dysfunction in transplant 
patients may refl ect underlying disease severity, which 
may increase infl ammation and cause nonspecifi c neu-
rocognitive defi cits that do not necessarily refl ect 
underlying neuronal dysfunction. 9,31 In lung patients, 
however, there is some indication that neurocognitive 
function may independently predict mortality 32 and 
poorer neurocognitive function is associated with 
poorer medication adherence, as well as systemic vas-
cular disease. 31 
 It is noteworthy that several medical factors that have 
previously been shown to be predictive of mortality, 
including 6-min walk distance, were not associated 
with survival in the present analyses. 3 However, it 
should be noted that in sensitivity analyses of our data 
we found that 6-min walk distance was signifi cantly 
predictive of mortality when our analyses were limited 
to individuals who survived   4 years (HR  5 0.63, 
95% CI [0.42, 0.93],  P  5 .022) (data not shown). There-
fore, it is possible that medical predictors may be 
important markers of risk during the fi rst few years 
following transplantation, but less predictive over 
longer-term follow-up time periods. 
 There are, however, limitations. First, of the 201 
patients randomized to INSPIRE who also received a 
transplant, only 132 were available for posttreatment 
assessments. Participants who were not available for 
posttreatment assessments did not differ from par-
ticipants with posttreatment data in age ( P  5 .117), 
baseline BDI-II levels ( P  5 .863), baseline STAI-S 
levels ( P  5 .078), 6-min walk distance ( P  5 .296), or 
native disease ( P  5 .203), suggesting that they were 
similar to other participants with posttreatment data. 
However, participants without posttreatment data 
were on the waitlist for a shorter amount of time 
compared with participants in the control condition 
(1.27 [SD  5 2.07] years vs 2.25 [SD  5 1.78] years, 
 P  , .001), and 42 participants underwent transplanta-
tion during the intervention time period ( Fig 1 ), sug-
gesting that their data were missing due to factors 
related to their transplant care and not differences in 
medical factors that also would have impacted sur-
vival. Second, our assessment of neurocognitive func-
tion only sampled a limited number of neurocognitive 
domains. Although our battery was designed to achieve 
and poorer health locus of control 29 have been shown 
in some studies to increase the risk of mortality follow-
ing transplant, although fi ndings have been inconsis-
tent. 5 In addition, studies examining pretransplant 
quality of life have not found a relationship between 
poorer function and increasing rates of mortality. 30 
Surprisingly, in the present study, we did not fi nd a 
relationship between preoperative depression, anxiety, 
and elevated rates of mortality following transplanta-
tion. Our fi nding that persistent depressive symptoms 
were predictive of subsequent survival is potentially 
important and warrants further investigation, partic-
ularly because baseline levels of depression were not 
predictive of survival. Our prior work has shown that 
persistent depressive symptoms following coronary 
artery bypass graft surgery are associated with reduced 
survival, 11 although the relationship between persistent 
depression and mortality has not previously been eval-
uated in lung transplant recipients. Further research 
is needed to identify those mechanisms that may con-
tribute to the increased risk of death among depressed 
transplant survivors. The present fi ndings may sug-
gest that individuals with depressive symptoms who 
do not remit or improve following treatment may be 
 Table 2— Proportional Hazards Analysis of Executive 
Function as a Predictor of Posttransplant Survival 
(n  5 86) 
 Predictor  HR  95% CI  P Value 
Wait list time, y 1.11 0.97, 1.26 .140
CF vs COPD 0.29 0.06, 1.30 .106
PF vs COPD 1.01 0.33, 3.07 .985
Other vs COPD 1.02 0.33, 3.09 .979
Age, 10 y 0.86 0.58, 1.26 .431
6-min walk distance, 500 ft 1.27 0.89, 1.82 .196
FEV 1 , 10% of normal 1.10 0.88, 1.38 .401
Education, y 1.00 0.88, 1.13 .963
Framingham Stroke Risk Profi le 1.10 0.97, 1.23 .133
Executive function 1.09 1.02, 1.07 .012
HR  5 hazard ratio. See Table 1 legend for expansion of other abbre-
viations.
 Table 3— Proportional Hazards Analysis of Memory as 
a Predictor of Posttransplant Survival (n  5 86) 
 Predictor  HR  95% CI  P Value 
Wait list time, y 1.12 0.98, 1.28 .093
CF vs COPD 0.44 0.11, 1.88 .265
PF vs COPD 1.00 0.34, 3.00 .997
Other vs COPD 0.93 0.29, 2.98 .907
Age, 10 y 0.94 0.63, 1.39 .749
6-min walk distance, 500 ft 1.23 0.85, 1.78 .270
FEV 1 , 10% of normal 1.09 0.87, 1.38 .447
Education, y 0.99 0.87, 1.12 .839
Framingham Stroke Risk Profi le 1.13 1.01, 1.28 .039
Memory 1.11 1.01, 1.23 .030
See Table 1 and 2 legends for expansion of abbreviations.
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